Indicated for the treatment of chronic Hepatitis C (CHC) in adults and adolescents: 🦠 Pan-Genotypic: Approved for Genotypes 1, 2, 3, 4, 5, and 6. 🏥 Renal Impairment: Safe for use in patients with any degree of renal impairment (CKD). 💊 Retreatment: Effective for patients who have failed prior treatments (DAA-experienced).

Dosage and administration

Packaging: 21 tablets per bottle (1-week supply). ⚠️ ADMINISTRATION PROTOCOL: 💊 Dose: Take 3 tablets at once, once daily. Total daily dose: 300 mg Glecaprevir / 120 mg Pibrentasvir. 🍔 With Food: Must be taken with food to ensure proper absorption. 📅 Duration: Standard course is 8 weeks (8 bottles). Duration may be 12 or 16 weeks for patients with cirrhosis or specific prior treatment failures.

Severe hepatic impairment (Child-Pugh C). Co-administration with Atazanavir or Rifampin. Pregnancy and breastfeeding. Use of ethinyl estradiol-containing contraceptives (may increase liver enzymes).

Mavixen is generally well-tolerated. Common adverse reactions include: 🤯 Neurological: Headache. 💤 General: Fatigue. 🤢 Gastrointestinal: Nausea (mitigated by taking with food). Pruritus (itching) is rare but possible.

Mavixen — Glecaprevir 100 mg + 40 mg, 21 pcs, Everest

100% original product

Active ingredient

Glecaprevir Pibrentasvir

Manufacturer

Everest

Dosage 100 mg + 40 mg

Dosage form Tablets

Tablets per pack 21

Mavixen (Glecaprevir + Pibrentasvir) Tablets

Name: Mavixen
Brand: Everest
SKU: PROD-132
Price: 50541 UAH
Availability: InStock

50541₴ ~~52739₴~~ -4%

Mavixen (Glecaprevir 100 mg + Pibrentasvir 40 mg) is a fixed-dose combination generic of Mavyret, offering a pan-genotypic cure for Hepatitis C.

Manufacturer: Everest Pharmaceuticals. Each bottle contains 21 tablets (a 1-week supply). It contains two distinct antiviral agents that target the virus at different stages of its life cycle.

Key Advantages:

1. ⚡ Short Course: It offers the shortest treatment duration available—typically just 8 weeks for most patients without cirrhosis.

2. 🛡️ Renal Safety: It is the preferred regimen for patients with severe kidney impairment, including those on dialysis.

✅ Benefit: High cure rates (>98%) across all genotypes (1–6).

Indicated for the treatment of chronic Hepatitis C (CHC) in adults and adolescents:

🦠 Pan-Genotypic: Approved for Genotypes 1, 2, 3, 4, 5, and 6.
🏥 Renal Impairment: Safe for use in patients with any degree of renal impairment (CKD).
💊 Retreatment: Effective for patients who have failed prior treatments (DAA-experienced).

Packaging: 21 tablets per bottle (1-week supply).

⚠️ ADMINISTRATION PROTOCOL:

💊 Dose: Take 3 tablets at once, once daily. Total daily dose: 300 mg Glecaprevir / 120 mg Pibrentasvir.
🍔 With Food: Must be taken with food to ensure proper absorption.
📅 Duration: Standard course is 8 weeks (8 bottles). Duration may be 12 or 16 weeks for patients with cirrhosis or specific prior treatment failures.

Severe hepatic impairment (Child-Pugh C).
Co-administration with Atazanavir or Rifampin.
Pregnancy and breastfeeding.
Use of ethinyl estradiol-containing contraceptives (may increase liver enzymes).

Mavixen is generally well-tolerated. Common adverse reactions include:

🤯 Neurological: Headache.
💤 General: Fatigue.
🤢 Gastrointestinal: Nausea (mitigated by taking with food).
Pruritus (itching) is rare but possible.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 13.03.2026

Active ingredient

Glecaprevir Pibrentasvir

Manufacturer

Everest

Dosage 100 mg + 40 mg

Dosage form Tablets

Tablets per pack 21

100% original product

Delivery across Ukraine

Alternatives

What Customers Say

No reviews yet

Your review can be the first!

Mavixen (Glecaprevir + Pibrentasvir) Tablets

Similar products

Maviret

What Customers Say

No reviews yet

Contact us

Request a call